A Novel HAGE/WT1-ImmunoBody(®) Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone

Many cancers, including myeloid leukaemia express the cancer testis antigen (CTA) DDX43 (HAGE) and/or the oncogene Wilms’ tumour (WT1). Here we demonstrate that HAGE/WT1-ImmunoBody(®) vaccines derived T-cells can kill ex-vivo human CML cell lines expressing these antigens and significantly delay B16...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Oncol
Päätekijät: Almshayakhchi, Rukaia, Nagarajan, Divya, Vadakekolathu, Jayakumar, Guinn, Barbara-Ann, Reeder, Stephen, Brentville, Victoria, Metheringham, Rachael, Pockley, A. Graham, Durrant, Lindy, McArdle, Stephanie
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2021
Aiheet:
Oncology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8273701/
https://ncbi.nlm.nih.gov/pubmed/34262856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.636977
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia